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Background: The recent Emergency Laparotomy Pathway Quality Improvement Care (ELPQuiC) study
showed that the use of a specific care bundle reduced mortality in patients undergoing emergency
laparotomy. However, the costs of implementation of the ELPQuiC bundle remain unknown. The aim of
this study was to assess the in-hospital and societal costs of implementing the ELPQuiC bundle.
Methods: The ELPQuiC study employed a before–after approach using quality improvement methodol-
ogy. To assess the costs and cost-effectiveness of the bundle, two models were constructed: a short-term
model to assess in-hospital costs and a long-term model (societal decision tree) to evaluate the patient’s
lifetime costs (in euros).
Results: Using health economic modelling and data collected from the ELPQuiC study, estimated
costs for initial implementation of the ELPQuiC bundle were €30 026⋅11 (range 1794⋅64–40 784⋅06)
per hospital. In-hospital costs per patient were estimated at €14 817⋅24 for standard (non-care bundle)
treatment versus €15971⋅24 for the ELPQuiC bundle treatment. Taking a societal perspective, lifetime
costs of the patient in the standard group were €23 058⋅87, compared with €19 102⋅37 for patients
receiving the ELPQuiC bundle. The increased life expectancy of 4months for patients treated with the
ELPQuiC bundle was associated with cost savings of €11 410⋅38 per quality-adjusted life-year saved.
Conclusion: Implementation of the ELPQuiC bundle is associated with lower mortality and higher
in-hospital costs but reduced societal costs.
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Introduction
Emergency laparotomy has been shown to have a high
mortality rate1,2. Several studies3–5 have now demon-
strated that significant reductions in mortality are possi-
ble using an evidence-based care bundle approach, which
streamlines processes, standardizes care, improves quality
and ultimately reduces mortality and morbidity.
One study, the Emergency Laparotomy Pathway Qual-
ity Improvement Care (ELPQuiC) bundle, was conducted
in four general district hospitals in England and used a
six-point pathway3. The six points were: prompt assess-
ment using an early warning score; early use of antibiotics
when sepsis was diagnosed; operation within 6 h of a deci-
sion to operate; use of intraoperative goal-directed therapy;
ICU admission for all patients after surgery; and consul-
tant surgeon and anaesthetist involvement throughout the
pathway.
For the ELPQuiC study, the quality improve-
ment methodology used was based on the ‘model for
improvement’6. This included ongoing feedback and eval-
uation of data and performance throughout the study to
assist implementation of the care bundle. The publica-
tion of this project followed the recommendations of the
Standards for Quality Improvement Reporting Excellence
(SQUIRE) statement7.
Despite growing evidence showing improved out-
comes linked to clinical pathways3–5, concerns about
additional costs often hamper widespread and rapid
adoption8. Implementation costs, costs due to increased
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Fig. 1 aUnderlying pathology and b operative procedures performed (as a proportion of all patients) before (299 patients) and after (427
patients) implementation of the Emergency Laparotomy Pathway Quality Improvement Care (ELPQuiC) bundle. GI, gastrointestinal
ICU admissions, and the presence of consultant surgeons
and consultant anaesthetists may increase the hospital
expenditure costs for survivors and lead to increased
hospital costs. This problem is further aggravated by
the current UK National Health Service (NHS) reim-
bursement scheme, which not only incurs a significant
shortfall for emergency laparotomy9,10 but also, owing
to a lack of long-term outcomes and cost-effectiveness
studies, often ignores potential long-term cost savings for
society.
Under such circumstances, cost-effectiveness studies
can be used to assess costs and benefits. By combin-
ing quantitative and qualitative data, the most efficient
and cost-effective solution for a clinical problem can be
evaluated11–13. Those outcomes help decision-makers
(NHS funding) to derive evidence-based decisions on
long-term costs savings and, importantly, individual and
societal wellbeing14–16.
The primary aim of this study was to compare the
in-hospital costs of a patient receiving bundled care versus
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 262–269
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Table 1 Model input data
Unit Value* Reference
Implementation
Training, supervision and administration
Salary
Nurses € 29 553⋅15 (19 242–38 484) 31
Consultants € 100856⋅05 (96 517⋅87–130140⋅06) 32
Registrars € 88 383⋅00 (66 705⋅60–110 060⋅39) 32
Time commitment (per week)
Nurses (3) h 6⋅0 (3–24) Trial data
Consultants (2) h 12⋅0 (4–16) Trial data
Registrars (3) h 6⋅0 (2–24) Trial data
Cardiac output monitors € 24 493⋅78 11
Bundle
Tazocin® € 19⋅50 30
Operating room (rate/min) € 20⋅52 3
Incremental operating room time min 5⋅17 Trial data
Cost of goal-directed fluid therapy/patient € 129⋅56 (128⋅28–615⋅74) 11
Consultant anaesthetist (incremental time commitment) % 17 Trial data
Consultant surgeon (incremental time commitment) % 18 Trial data
Variable costs
Cost of ward bed € 256⋅56 19
Costs of ICU bed (levels 1–5) € (1113⋅47–2238⋅49) 19
Long-term costs
Costs of long-term complication € 406⋅65 (304⋅02–507⋅99) 33
Utility†
After 12months 0⋅66 23
After a complication 0⋅51 23
*Values in parentheses are ranges. †Utility is a ratio (0–1): 0 is the utility of death; 1 is the utility of full health. £1= €1⋅2828 (exchange rate 20 March
2016). Tazocin®: Pfizer, Tadworth, UK.
standard care, with a secondary aim of modelling the
cost-effectiveness of the bundle versus standard treatment
over the patient’s lifetime. In addition, the existing NHS
reimbursement scheme for emergency laparotomies was
assessed to identify whether current funding is commen-
surate for individual hospitals and society in general.
Methods
This was a post hoc analysis of the ELPQuiC project,
using data from the original ELPQuiC publication3. The
analysis was conducted in accordance with the Consoli-
dated Health Economic Evaluation Reporting Standards
(CHEERS) guidelines17.
To assess the cost-effectiveness of the ELPQuiC pathway,
two decision trees were designed. A hospital management
perspective was adopted for the short-term model. This
looked at costs associated with implementation of the path-
way during the in-hospital time of the patient. The main
outcomes for this model were overall costs per patient of
implementing the ELPQuiC bundle compared with stan-
dard care.
To construct a decision tree from the hospital’s per-
spective, further data from the ELPQuiC database were
obtained that had not been published previously. The
PostoperativeMorbidity Score (POMS)18 was collected for
each patient in the ELPQuiC study on days 3 and 7 after
surgery and costed usingNHS reference costs19. Input data
were derived from the study and included effectiveness data
(30-day and in-hospital mortality and morbidity) and cost
data (resource utilization during the study period, imple-
mentation and in-hospital costs).
To assess long-term benefit, a societal perspective was
undertaken. This looked at estimated life expectancy of
all survivors and the likely cost to gain one additional year
of living in perfect health (1 quality-adjusted life-year,
QALY). To determine the QALY value, the remaining
life expectancy for each surviving patient was calculated20,
and a utility value was assigned to various stages of the
disease process21–23. For example, if an individual has a
life expectancy of 7 years, and the QALY value is 0⋅66
for the first year after operation, 0⋅71 for the second and
third years, and 0⋅75 for the last 4 years, the adjusted life
expectancy is 5⋅08 years (1*0⋅66+ 2*0⋅71+ 4*0⋅75). Finally,
life expectancy was adjusted to account for increased risk
of death following an ICU episode and complications after
surgery24–27.
Long-term effects were calculated by extrapolating the
results using external evidence on utility and risk of death
after survival in the ICU21–26. A predictive modelling
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 262–269
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Table 2 Resource use and outcome of patients undergoing
emergency laparotomy with standard care compared with
ELPQuiC care-bundled care
Standard care
(non-ELPQuiC)
ELPQuiC
bundle care
30-day mortality (%) 14⋅0 11⋅5
Length of stay
ICU (days)
Level 1 7⋅3 0⋅2
Level 2 1⋅6 2⋅0
Level 3 2⋅6 1⋅7
Ward (days) 8⋅7 14⋅6
Costs (€)
ICU 15174⋅37 6338⋅44
Ward 3140⋅04 5261⋅79
Complications 8242⋅12 10137⋅71
In-hospital death 15 326⋅77 10404⋅66
Implementation 30 026⋅11
ELPQuiC bundle 361⋅11 (323⋅78–878⋅97)
Life expectancy (years) 6⋅70 7⋅21
Life expectancy
(quality-adjusted years)
4⋅53 4⋅88
Cost-effectiveness (short term)
Costs (€) 14 817⋅24 15971⋅24
Effectiveness/utility* 0⋅7 0⋅9
ICER (€ per patient) – 12 066⋅00
Net monetary benefit (€) 9781⋅73 14262⋅43
Cost-effectiveness (societal)
Costs (€) 23 058⋅87 19102⋅37
Effectiveness/utility* 4⋅5 5⋅87
ICER (€ per patient) – −11410⋅38
Net monetary benefit (€) 28 185⋅54 33529⋅20
Values are mean (range). *Utility is a ratio (0–1): 0 is the utility of death;
1 is the utility of full health. £1= €1⋅2828 (exchange rate 20 March 2016).
ELPQuiC, Emergency Laparotomy Pathway Quality Improvement Care;
ICER, incremental cost-effectiveness ratio.
technique was then applied. Follow-up data from the study
were combined with published research data to estimate
long-term costs and outcomes.
Costs
Costs comprised implementation costs, in-hospital costs,
and postdischarge/lifetime costs. International prices, if
applicable, were converted to euros using 2016 exchange
rates (conversion day 20 March 2016); £1= €1⋅2828. A
discount rate of 3⋅5 per cent was applied in accordance with
NHS guidelines28.
Costs for implementing the bundled pathway, including
planning, training and supervision, were calculated. Addi-
tional equipment purchased, such as monitoring devices,
and pharmaceutical costs, were also estimated29–32.
In-hospital costs were calculated based on length of stay
and the various levels of care received by each individual
patient over time, multiplied by NHS reference costs19.
Ward, ICU (levels 1–3), and postanaesthetic care unit
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Fig. 2 Cost-effectiveness acceptability curve for standard and
bundle treatments, illustrating the uncertainty surrounding the
estimate of the cost-effectiveness analysis
periods and reoperations were accounted for and calcu-
lated as a cost per day. Additional human resource time
included anaesthetic and surgical consultants caring for the
patient during surgery32, as well as ICU nurses performing
goal-directed therapy31.
For patients who died in hospital, actual care received and
length of stay for each individual up to the date of death
were determined. Indirect costs (such as loss of income)
were accounted for by using a flat rate.
Cost-effectiveness analysis
Two separate decision trees were modelled, from a hospital
and a societal perspective, and results were displayed as
cost per in-hospital patient and cost per QALY gained. All
costs and outcomes were based on a bootstrap analysis with
10 000 replications and presented as means with 95 per
cent confidence intervals. A cost-effectiveness acceptability
curve was generated to display the degree of acceptance
relative to the costs generated by the intervention.
Sensitivity analysis
A deterministic and probabilistic sensitivity analysis
was conducted to account for assumptions in the input
parameter and to determine the robustness of the model.
In the first step, discount rate, length of stay, number
of patients per site, life expectancy following high-risk
surgery, and utility values were examined using a one-way
sensitivity analysis. The key drivers (most ‘sensitive’
parameters) were then subjected to two- and three-way
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 262–269
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Bundle
Die
Complication
Survive
Die Survive
Survive
Die
Complication 
Survive 
Survive
Die
Standard care
No complication Survive
In-hospital death
In-hospital death
No complication
Emergency laparotomy
€17 124·82/4·87 QALY
€20 671·73/4·53 QALY
€25 993·45/6·1 QALY
€16 417·4/0 QALY
€19 698·35/9·3 QALY
€22 132·13/4·53 QALY
€17 977·94/5·42 QALY
€20 346·95/0 QALY
€22 534·25/6·1 QALY
€11 259·65/0 QALY
€14 540·6/9·3 QALY
€23 806·15/0 QALY
Bundle
€17 124·82/4·87 QALY 
Fig. 3 Societal model. At the initiation node, a patient enters either the standard or the Emergency Laparotomy Pathway Quality
Improvement Care (ELPQuiC) bundle branch. Throughout the hospital stay, the individual may die, develop complications or remain
alive without complication, and accrues costs. Mean outcomes are calculated by summing the probability of reaching each state with the
input parameter (costs and utility). Costs include the main expenses (in-hospital, pharmaceutical, follow-up costs) accrued during the
observation period. QALY, quality-adjusted life-years gained by receiving standard or bundle care
analyses to test the combined parameter uncertainty. For
a better understanding, key drivers were then displayed
graphically in a tornado diagram.
Results
A total of 299 patients underwent emergency laparotomy
before implementation of the bundle in this study, com-
pared with 427 consecutive patients after implementation.
The underlying pathology and surgery performed, derived
from the ELPQuiC database, are shown in Fig. 1. Overall,
the indications for surgery were similar in the two groups
of patients. Bowel resection was performed more com-
monly in the postimplementation group, whereas more
patients had ‘unknown’ surgical procedures in the pre-
implementation group. The overall risk-adjusted mortal-
ity rate decreased from 15⋅6 to 9⋅6 per cent (risk ratio
0⋅61, 95 per cent c.i. 0⋅45 to 0⋅84; P= 0⋅002). The over-
all crude 30-day mortality rate decreased from 14⋅0 (95
per cent c.i. 10⋅1 to 18⋅0) per cent in the baseline group
to 10⋅5 (7⋅6 to 13⋅5) per cent following implementation
of the care bundle. Mean in-hospital stay was 11 (i.q.r.
7–23) days before implementation and 11 (6–21) days after
implementation.
Short-term model: cost-effectiveness
Model input data are shown in Table 1. Mean total spend-
ing for implementing the bundle at each hospital was
€30 026⋅11 (range 1794⋅64–40 784⋅06), driven largely by
the purchase of cardiac output devices, as well as teach-
ing and supervision by a consultant trainer. Assuming an
average equipment amortization of 5 years and an eli-
gible patient population of 50 patients per site per year,
implementation was associated with a mean cost of €600⋅48
(range 17⋅96–2039⋅27) per patient.
Incremental mean costs related to the ELPQuiC bun-
dle (additional presence of consultant in theatre, pharma-
ceuticals and goal-directed therapy) were €361⋅11 (range
323⋅78–878⋅97) per patient (Table 2).
For the short-term (hospital-based) model, mean
total costs per patient associated with the bundle were
€15 971⋅24, compared with costs for standard treat-
ment of €14 817⋅24. Adjusting for decreased survival in
the standard treatment group (0⋅7 life-years versus 0⋅9
life-years in the ELPQuiC group) revealed an incremental
cost-effectiveness ratio (ICER) of €12 066⋅66 per patient
(Table 2).
Using POMS data and the short-term hospital model
decision tree, it was identified that the occurrence
of postoperative complications gave rise to addi-
tional costs. Patients who developed complications
incurred costs of €10 367⋅72–25 031⋅66, compared with
€3039⋅72–18 163⋅93 in patients who had no complications.
The highest expenses were found in the group that received
standard care, required ICU admission, and developed a
complication (mean cost €25 031⋅66). The main drivers
were complication costs and length of stay in the ICU.
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 262–269
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Costs for patients who died were €15 326⋅77 per patient
in the standard group and €10 404⋅66 per patient in the
ELPQuiC group.
To address the uncertainty around the estimates of
mean costs and outcomes, a cost-effectiveness accept-
ability curve was generated (Fig. 2). This can be used to
display the probability of being cost-effective at various
thresholds (the decision-maker’s willingness-to-pay). A
range of cost-effectiveness thresholds was plotted on the
horizontal axis against the probability that the intervention
would be cost-effective at that threshold on the vertical
axis. Assuming the currently accepted NHS threshold of
£30 000 (€38 484)/QALY gained, the intervention was 90⋅7
per cent cost-effective. Even when a willingness-to-pay of
£0 (€0)/QALY gained was assumed, the probability of the
intervention being considered cost-effective was still 70
per cent.
Societal model: cost-effectiveness
Mean(s.d.) long-term costs associated with the ELPQuiC
bundle were €19 102⋅37(14 661⋅12) with a mean(s.d.)
quality-adjusted life expectancy of 4⋅88(0⋅28) years, com-
pared with €23 058⋅87(10 227⋅76) and 4⋅53(0⋅25) years
respectively for standard care. The mean discounted and
quality-adjusted life expectancy in the intervention group
increased by 0⋅34 life-years, or 4months. The calculated
ICER was negative with €− 11 484⋅40/QALY, which is a
result of positive (more effective) clinical outcome in the
nominator and negative (lower) costs of the pathway in the
denominator (Table 2).
Detailed outcomes of the long-term (societal perspective)
decision tree are shown in Fig. 3.
Discussion
Using health economic modelling and data collected
from the ELPQuiC study, estimated costs for initial
implementation of the ELPQuiC bundle were estimated
at €30 026⋅11 (range 1794⋅64–40 784⋅06) per hospital.
In-hospital costs per patient were estimated at €14 817⋅24
for standard (non-care bundle) treatment versus €15 971⋅24
for the ELPQuiC bundle. Improved survival for patients
receiving the ELPQuiC bundle was associated with
increased hospital costs of €12 066⋅66 per additional life
saved. The long-term model showed that the interven-
tion was both more effective (increased mean survival of
4months) and led to lower costs to society, with savings
of €3956⋅50 per survivor. The ICER met the commonly
accepted NHS threshold of £30 000 (€38 484)/QALY.
Sensitivity analysis confirmed the robustness of the model
results.
The ELPQuiC pathway not only improves clinical care
but also reduces mortality and is cost-effective in the
long term. Therefore, it should be recommended as a
quality improvement programme to policy and financial
decision-makers.
In this evaluation, historical mean hospital costs of
€14 817⋅24–15 971⋅24 per patient undergoing emergency
laparotomy were calculated. This is similar to the aver-
age expenses reported by Shapter and colleagues9 of
£13 000 (€16 676⋅40) and by Murray and co-workers34
of median £9282 (range 6222–14 400) (€11 906⋅95
(7981⋅58–18 472⋅32)). Although there are variations
in NHS reimbursement rates (payment by results tariffs)
of approximately £4000–7000 (€5131⋅20–8979⋅60) per
emergency case35, these results confirm that significant
NHS funding deficits exist for each patient (funding
shortfall of £4550–6450 (€5836⋅74–8274⋅06)). Such
funding gaps may have detrimental effects on the will-
ingness of providers to invest in quality improvement
programmes. This ongoing deficit highlights the need for
cost-effectiveness modelling to demonstrate the benefits
of investment in high-cost clinical areas36.
Some of the calculated costs associated with bundle
implementation may be excessive. In particular, the incre-
mental costs of introducing goal-directed fluid therapy or
the additional resources required to continue this therapy
in the ICUmay be inflated. If this is the case, the ELPQuiC
bundle may be cheaper than described, thereby lowering
the cost per additional life saved.
The use of bundles of care is now widespread. Many
observers associate improved outcomes with reduced costs.
Although this may be aspirational, the results may not be
forthcoming owing to difficulty in assessing costs. The use
of evidence from care bundles, such as ELPQuiC, will
allow commissioners to identify areas of spending where
maximum return, in terms of lives saved or economic
benefit to society overall, can be most effective.
This is the first study comparing the economic impact
of an emergency laparotomy pathway with standard care.
Thus, although these findings indicate a positive effect on
outcome and costs, caution should be applied. There are
several limitations that need to be considered. First, no
long-term study data on quality of life and cost data were
available. The ELPQuiC study reported both in-hospital
and 30-day mortality; longer-term outcomes were not
available. Suggestions for using longer outcome data were
published after completion of the ELPQuiC project37.
The model used in this study combined trial input data
with international evidence on long-term data. This may
introduce bias, as utility of life and costing may vary across
countries and healthcare systems. As this approach was
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 262–269
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the only possibility to model long-term outcomes, those
parameters were tested in a sensitivity analysis.When vary-
ing the parameter, and assuming maximal costs and mini-
mal utility for long-term survival, the model still revealed
robust data and the pathway remained the cost-effective
strategy.
Second, the life expectancy of survivors was adjusted to
account for the hazard ratio (HR) of survivors following
high-risk surgery and presenting with postoperative com-
plications. In a 15-year follow-up study, Rhodes et al.25
found an HR of 1⋅93; thus a similar value was used for
the present study population. In the sensitivity analysis, the
ICER remained negative when varying the life expectancy,
indicating that even worst life expectancy was associated
with the care bundle remaining the dominant treatment.
Length of patient stay is the primary determinant of hospi-
tal costs. It may be that with a longer implementation time
ELPQuiC could reduce length of hospital stay and there-
fore overall hospital costs.
The ELPQuiC project was a quality improvement
project not a blinded RCT. ELPQuiC was designed not to
discover new evidence, but to assess the effect of consistent
delivery of evidence-based care for patients undergoing
emergency laparotomy. Criticism of this project may be
forthcoming, in particular the small number of participat-
ing sites, the non-randomization of patients, the lack of a
power estimate, the use of a ‘before and after’ approach,
and the fact that a formal, pre-experimental protocol is not
available. However, quality improvement work generally
describes improvement activities in a well-defined service
or problem. Quality improvement projects act as ‘proof of
concept’ rather than to define new knowledge as outputs
of RCTs. Following on from ELPQuiC, a larger-scale
quality improvement collaborative approach is now being
undertaken37.
The main strength of this study was costing patient care
from both a hospital and a societal perspective. Improve-
ment in mortality has been shown in this study to increase
costs (but within commonly accepted thresholds) for hos-
pitals, but to decrease overall costs to society. Further work
is warranted to continue to deliver improved mortality, but
also to reduce length of stay for patients undergoing emer-
gency laparotomy.
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